费内伦诺:它会改变游戏规则吗?
Dinesh Khullar1, Anish Kumar Gupta1, Kulwant Singh1
1Department of Nephrology and Renal Transplant Medicine, Max Super Speciality Hospital Saket, New Delhi, India.
Cardiac failure review
|January 28, 2025
概括
费内伦是一种非类固醇矿物质皮质类受体对手 (MRA),有效地减少了心力衰竭住院和心血管死亡在2型糖尿病和慢性病患者. 它提供了一个比类固醇MRA更安全的替代品,具有较少的高血和急性损伤风险.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 内分泌学 在内分泌学.
背景情况:
- 心力衰竭 (HF) 是心血管死亡的主要原因,患有慢性病 (CKD) 和2型糖尿病 (T2D) 的患者的风险更高.
- 目前的指导方针不充分解决HF管理中的并发症.
- 类固醇矿物质皮质类受体对抗剂 (MRA) 是有效的,但携带风险,如高血和急性损伤 (AKI).
研究的目的:
- 评估非类固醇MRAfinerenone的疗效和安全性,在患有HF和并发症的患者中.
- 评估finerenone对HF住院和心血管结果的影响.
- 为了比较finerenone的安全性与现有的类固醇MRAs.
主要方法:
- 对包括ARTS,ARTS-HF,FIDELIO-DKD,FIGARO-DKD和FINEARTS-HF在内的III期临床试验的分析.
- 包括患有降低,轻度降低或保留喷射分数的高炎患者,通常与CKD和T2D.
- 评估终点,如高频率住院,心血管死亡,高胆血症和AKI.
主要成果:
- 费内伦显著减少了HF住院 (22%在FIDELIO-DKD/FIGARO-DKD) 和心血管死亡.
- 与螺旋乳相比,使用菲内伦观察到的高血症和AKI事件较少.
- 在临床前和临床研究中注意到对心脏和脏组织的积极影响,包括抗炎和抗纤维性质.
结论:
- 菲内伦是一种安全有效的非类固醇MRA用于管理HF,特别是在CKD和T2D患者中.
- 与类固醇MRA相比,它提供了有利的风险益处概况,减少了关键不良事件.
- 目前正在进行的试验正在探索finerenone在各种HF表型和心代谢疾病管理中的作用.
更多相关视频
06:00Optimization of the Epimedii Folium Mutton-Oil Processing Technology and Testing Its Effect on Zebrafish Embryonic Development
Published on: March 17, 2023
412
09:00Microdissection of Primary Renal Tissue Segments and Incorporation with Novel Scaffold-free Construct Technology
Published on: March 27, 2018
7.4K
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
375
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
375
01:25Antihypertensive Drugs: Direct Renin Inhibitors
480
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
480
01:11Renal Failure: Dose Adjustments
61
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
61
01:31Factors Affecting Renal Clearance: Drug's Physicochemical Properties and Plasma Levels
166
Renal clearance of a drug is influenced by various factors, including its physicochemical properties and plasma levels. These factors play a significant role in determining how efficiently the kidneys eliminate a drug.
One important factor is the drug's molecular size. The kidneys readily excrete smaller molecules below 300 Daltons (Da). On the other hand, molecules weighing between 300 and 500 Da are excreted through both urine and bile. Larger molecules above 500 Da tend to be excreted...
One important factor is the drug's molecular size. The kidneys readily excrete smaller molecules below 300 Daltons (Da). On the other hand, molecules weighing between 300 and 500 Da are excreted through both urine and bile. Larger molecules above 500 Da tend to be excreted...
166
01:28Renal Drug Excretion: Tubular Secretion
114
Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...
114
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
462
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
462